Fu Liwu

FULL MEMBER (ACADEMICIAN) OF THE RUSSIAN ACADEMY OF FUNDAMENTAL AND SOCIAL SCIENCES NAMED AFTER ACADEMICIAN M.V. LOMONOSOV (2023), PROFESSOR.

Научная биография / Scientific Biography:

Personal Information:

Name: Liwu Fu

Gender: Male                                

Citizenship: Chinese Resident 

Date of Birth: Nov. 27, 1964         

Contact:

Professor, Director, Department of Experimental Research (Cancer Institute), Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China.

Address: #651, East, Dongfeng Rd, Guangzhou, 510060, China

Education

1999 to 2001, Postdoctoral Fellow,

Department of Pathology and Lab Medicine, Medical University of South Carolina. Charleston, USA.

Sept. 1993 to July 1996,  Ph.D. Program of Medicine,

Cancer Center, Sun Yat-Sen University of Medical Sciences (SUMS), (now rename to: Sun Yat-sen University), Guangzhou, 510060, P. R.China.

Sept.1990 to July 1993.  M. S.  Program of Medicine

Department of Toxicology, Sun Yat-Sen University of Medical Sciences (SUMS), (now rename to: Sun Yat-sen University), Guangzhou, 510080 P. R. China.   

Sept. 1982 to July 1987.  M.D.,

Department of Medicine, Guangdong Medical and Pharmaceutical College (rename to Guangdong pharmaceutical College since 1993), Guangzhou, 510024 P.R.China.

Work Experience

Jan. 2006 to present,  Professor, Director, Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. 

Jun. 2002 to Dec. 2005, Professor, Head, Department of Anticancer Drug, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. 

December 2001 to May 2002, Associate Professor, Department of Anticancer Drug, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China. 

1999 to 2001, Postdoctoral fellow, Department of Pathology and Lab Medicine, Medical University of South Carolina, USA.

Dec. 1998 to 1999, Associate Professor, Depute Head, Department of Anticancer Drug, Cancer Center, SUMS.

Jul. 1996 to Nov. 1998, Lecturer, Deputy Head, Department of Anticancer Drug, Cancer Center, SUMS, Guangzhou, 510060, P. R. China.

Jul. 1987 to Sept. 1990. Assistant,  Department of Toxicology, Guangdong Medical and Pharmaceutical College, Guangzhou, P. R. China.

Membership:

Jul. 2009 to present: Chairman of Board of directors, Guangdong Cancer Pharmacological Society.

Oct. 2006 to present: Associate Director, Cancer Pharmacology and Chemotherapy Section, Chinese Pharmacological Society.

Oct. 2006 to present: Associate Director, Anticancer Drug Section, Chinese Anticancer Society.

Jun. 2003 to present: Active member of AACR. Jun. 2002 to present: Member of Board of Directors, Guangdong Pharmacological Society ,

Sept. 1994 to Present: Member of Chinese Pharmacological Society.

Editorial Member/Reviewer of Scientific Journals

Editorial Board of Journals

Drug Resistance Updates (2022-)

Mol Pharmacol (2013. 3-)

Clinical Cancer Drugs（2012.4-）

American Journal of Cancer Research（2010.12.-）

Recent Patents on Anti-Cancer Drug Discovery (2009.12.-)

Chinese Journal of Cancer （2004.2.-）

Chinese Journal of Clinical Pharmacology（2004.5.-）

Chinese Journal of New Drug (2009.3-)

Acta Pharmaceutica Sinica (2008.3-)

Acta Pharmaceutica Sinica B （2014.-）

Reviewer of International Scientific Journals

Cancer Res

Nat Commun

Clin Cancer Res

J Bio Chem

Cancer Chemotherapy and Pharmacology

Biochemical Pharmacology

Apoptosis

Life Sciences

Cancer Letters

Acta Pharmacological Sinica  (Chinese Journal)

Chinese Pharmacological Bulletin  (Chinese Journal)

Journal of Pharmacology and Experimental Therapeutics (JPET)

Cell Death and Disease

Active Research fields:

1. Cancer pharmaclogy
2. Cancer chemotherapy
3. Cancer multidrug resistance and TKIs’ resistance

Personalized chemotherapy

Key words: Multidrug Resistance;  Tyrosine kinase inhibitor; ABC transporters; Exosomes; Cancer; Cancer stem cells.

Publication:

Peer-Reviewed Journal Papers (* stands for corresponding author)

2022

• Fan J, Bellon M, Ju M, Zhao L, Wei M, Fu L*, Nicot C*. Clinical significance of FBXW7 loss of function in human cancers. Mol Cancer. 2022 Mar 26;21(1):87.
• Fan Y, Tao T, Guo Z, Wah To KK, Chen D, Wu S, Yang C, Li J, Luo M, Wang F, Fu L*. Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo. Mol Ther Oncolytics. 2022 Feb 16;24:636-649.
• Fu L*, Chen ZS*. Redox signaling-governed drug-tolerant persister cancer cell: a key spark of treatment failure. Signal Transduct Target Ther. 2022 Mar 17;7(1):89. 
• Zhang Y*, Li C*, Xia C, Wah To KK, Guo Z, Ren C, Wen L, Wang F, Fu L*, Liao N*. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Commun Signal. 2022 Sep 14;20(1):142.

2021

• Wu S, Luo M, To KKW, Zhang J, Su C, Zhang H, An S, Wang F, Chen D, Fu L*. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Mol Cancer. 2021 Jan 18;20(1):17. 
• Rong QX#, Wang F#, Guo ZX, Hu Y, An SN, Luo M, Zhang H, Wu SC, Huang HQ*, Fu LW*. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma. Mol Cancer. 2021 May 29;20(1):80. 
• Yang C, Yang C, Yarden Y, To KKW, Fu L*. The prospects of tumor chemosensitivity testing at the single-cell level. Drug Resist Updat. 2021 Jan;54:100741.
• Su C#, Zhang J#, Yarden Y, Fu L*. The key roles of cancer stem cell-derived extracellular vesicles. Signal Transduct Target Ther. 2021 Mar 8;6(1):109.
• Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, An S, Wu S, Yang C, Chen D, Xu M, Cai M, To KKW, Fu L. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021 Mar 24;8(10):2003404. 
• Luo M#, Xia Y#, Wang F#, Zhang H, Su D, Su C, Yang C, Wu S, An S, Lin S*, Fu L*. PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta Pharm Sin B. 2021 Oct;11(10):3120-3133. 
• Zhang H, Fu L*. The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment. Acta Pharm Sin B. 2021 Jun;11(6):1400-1411. 
• Huang L, Guo Z, Wang F, Fu L*. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. 
• Yang K, Wang F, Zhang H, Wang X, Chen L, Su X, Wu X, Han Q, Chen Z, Chen ZS, Fu L*. Target Inhibition of CBP Induced Cell Senescence in BCR-ABL-T315I Mutant Chronic Myeloid Leukemia. Front Oncol. 2021 Jan 8;10:588641.

2020

• Wang X, Wang F, Zhong M, Yarden Y, Fu L*. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. Mol Cancer. 2020 May 2;19(1):81.
• Cui C, Yang J, Li X, Liu D, Fu L*, Wang X*. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020 Mar 14;19(1):58.
• STTT (in press)
• Wang F, Qi XM, Wertz R, Mortensen M, Hagen C, Evans J, Sheinin Y, James M, Liu P, Tsai S, Thomas J, Mackinnon A, Dwinell M, Myers CR, Bartrons R, Fu L*, Chen G*. p38gamma MAPK is essential for aerobic glycolysis and pancreatic tumorigenesis. Cancer Res. 2020 Jun 24:3281
• Zeng F#, Wang F#, Zheng Z#*, Chen Z, Wah To KK, Zhang H, Han Q, Fu L*. Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo. Acta Pharm Sin B. 2020 May;10(5):799-811.
• Wang F#, Li D#, Zheng Z, Kin Wah To K, Chen Z, Zhong M, Su X, Chen L*, Fu L*. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1. J Exp Clin Cancer Res. 2020 Mar 12;39(1):50.
• Xu L#, Huang J#, Liu J#, Xi Y, Zheng Z, To KKW, Chen Z, Wang F, Zhang Y*, Fu L*. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. Mol Ther Oncolytics. 2020 Mar 27; 16: 100–110.
• Fu L*, Editorial of special issue on pharmacotherapeutics of digestive tumors. Gastroenterology Report, 2020
• Zhang JY, Yan YY, Li JJ, Adhikari R, Fu LW*. PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Front Pharmacol. 2020 May 15;11:722.